Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S. P., . . . Jansen, K. U. (2020). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. MedRxiv. doi:10.1101/2020.06.30.20142570
Link: https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1

Carnegie Mellon University

- Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
- SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice
- First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine 

COVID-19 Genetic Engineering Articles from medRxiv

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Keech, C., Albert, G., Reed, P., Neal, S., Plested, J. S., Zhu, M., . . . Glenn, G. M. (2020). First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine. MedRxiv. doi:10.1101/2020.08.05.20168435

Link: https://www.medrxiv.org/content/10.1101/2020.08.05.20168435v1

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Tian, J., Patel, N., Haupt, R., Zhou, H., Weston, S., Hammond, H., . . . Smith, G. (2020). SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice. MedRxiv. doi:10.1101/2020.06.29.178509

Link: https://www.biorxiv.org/content/10.1101/2020.06.29.178509v1

Learn Before

Related